We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Product News

CEVEC and Catalent Pharma Solutions Offer Joint Cell Line Development Service

Offering combines the benefits of CEVEC’s human cell line, CAP-Technology, with Catalent’s unique GPEx® Technology to generate high expressing stable human cell lines.
Product News

BiondVax Announces Positive Phase IIa Results for Universal Flu Vaccine

BiondVax’s Multimeric-001 Universal Influenza Vaccine successfully meets primary and secondary endpoints with strong safety and immunogenicity data in 200 participants.
Product News

BiondVax Announces Positive Phase IIa Results for Universal Flu Vaccine

BiondVax’s Multimeric-001 Universal Influenza Vaccine successfully meets primary and secondary endpoints with strong safety and immunogenicity data in 200 participants.
Product News

Inviragen Initiates Phase 1 Study of Hand, Foot and Mouth Disease Vaccine in Singapore

A highly purified virus particle preparation designed to protect against HFMD caused by enterovirus 71 (EV71).
Product News

Vetter Invests in Additional Lyophilization Capacity

A leader in aseptic filling increases number of freeze-dryers by 30 percent.
Product News

Oxford Expression Technologies Launches VLP Vaccine Production Services

The VLP platform offers huge potential for use as a highly effective antiviral vaccine.
Product News

First Patients are Vaccinated in IMPRINT, immatics’ Pivotal Phase III Trial with IMA901 in Patients with RCC

The trial is designed to demonstrate the overall survival benefit of IMA901 in combination with standard first-line therapy in RCC patients.
Product News

Novozymes Biopharma to Unveil New Research into the Production of Proteins with Extended Circulatory Half-life at Next Generation Protein Therapeutics Summit

New presentation coincides with launch of Albufuse®Flex albumin fusion technology, designed to overcome challenges associated with the therapeutic use of peptides and proteins.
Product News

BiondVax to Present Phase IIa Results at 2011 BIO International Convention

The Phase IIa clinical trial was a randomized, double-blind, safety and immunogenicity study in 200 healthy volunteers, aged 18-49, being conducted at two clinical research centers in Israel.
Product News

m2p-labs on Course for Growth

m2p-labs reaches break-even point and strengthens growth with new capital.
Advertisement